Pharmaceutical contract manufacturers (CDMOs) need to rethink how they prevent contamination in drug production. This is what Kieran Falvey from Pharmalliance Consulting Ltd. argues in a guest column on Outsourced Pharma.
In the past, many CDMOs managed contamination through separate procedures, inspections, and fixes made after problems occurred. New regulations, especially the updated EU GMP Annex 1, now require a much more comprehensive approach called a Contamination Control Strategy (CCS).
A CCS is a documented plan that shows how contamination risks are identified, prevented, monitored, and controlled across the entire facility—not just within individual processes or products. Regulators want evidence that contamination prevention was built into the operation from the start, rather than pieced together from many separate procedures.
This is especially challenging for CDMOs because they often manufacture products for multiple clients in the same facility. Different products, shared equipment, personnel movement, and varying client requirements all increase contamination risks.
Falvey says many existing contamination programs have three common weaknesses:
- They focus on individual products rather than the whole facility.
- Important facility design decisions (such as cleanroom layouts and airflow systems) are not clearly linked to contamination-risk assessments.
- Environmental monitoring programs often evolve reactively after problems occur rather than being based on a systematic risk analysis.
To address these issues, the author introduces Contamination Control by Design (CCbD). CCbD is a methodology that builds contamination prevention into facility design, processes, and operations from the beginning. The goal is to create a contamination control system that is proactive, risk-based, and easy to justify during inspections.
Main takeaway
CDMOs can no longer rely on a collection of SOPs and monitoring programs to satisfy regulators. They need a facility-wide, risk-based contamination strategy that is built into the design and operation of the site. The article introduces CCbD as a practical way to achieve this and prepare for regulatory inspections.
Picture: unsplash
Bron: www.outsourcedpharma.com